Nuvalent, Inc.
Status: Publicly traded
Direct answer
Nuvalent, Inc. is publicly traded on NASDAQ under the ticker NUVL.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially,...
Can you invest in Nuvalent, Inc.?
Yes. Nuvalent, Inc. is publicly traded on NASDAQ under the ticker NUVL.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Nuvalent, Inc.
Detailed equity research is provided by MarketSnap.